UT Health San Antonio MD Anderson Cancer Center | Strategic Alliance Partners

Latest from UT Health San Antonio MD Anderson Cancer Center

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 06, 2021

Article

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 07, 2020

Video

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 01, 2020

Video

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Mesa on Management Strategies for MPNs

October 23, 2020

Video

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16, 2020

Video

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15, 2020

Video

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.